November 6, 2017 — Elderly patients undergoing percutaneous coronary intervention (PCI) often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk.

November 6, 2017 – The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow FFR-CT Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). Under the APC payment system, hospitals enrolled in Medicare that bill CMS for the HeartFlow FFR-CT Analysis for Medicare patients will be eligible for reimbursement at a rate of $1,450.50 for the technical component of the test. This payment rate will take effect on Jan.

November 3, 2017 — Biotronik's Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during the 2017 Transcatheter Cardiovascular Therapeutics Annual Conference (TCT 2017), Oct. 29-Nov. 2 in Denver.

November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests statins are having a positive impact, according to an observational study in nearly 49,000 patients. The study was presented at the Association of Southeast Asian Nations (ASEAN) Federation of Cardiology Congress 2017 (AFCC2017).

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of October, based on website analytics of the month’s 163,117 pageviews:

 

Top Cardiology Technology Articles

1. First Smartphone Compatible Insertable Cardiac Monitor Cleared by FDA

November 3, 2017 — VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C round of funding to $38 million. The round was led by MVM and Baxter Ventures. This funding will help VitalConnect in launching the VitalConnect Platform and VitalPatch wearable biosensor in hospitals and outpatient settings across the nation.

Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System. The RXi Mini System debuted at the 29th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver.

The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.

November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the Boston Scientific Watchman device to warfarin in patients with nonvalvular atrial fibrillation found that the first composite co-primary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority. However, the second co-primary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority.
The B. Braun Sequent Please drug-eluting balloon.
DARE trial results presented at TCT 2017 show drug coated balloons are equal to the Xience stent in treating restenosis.

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-eluting bAlloon for in-stent Restenosis) multicenter, randomized clinical trial evaluated the performance of the B. Braun Sequent Please drug-eluting balloon (DEB) vs. the Abbott Xience everolimus-eluting stent (EES) in patients with ISR. The study found the DEB was non-inferiority to the drug-eluting stent (DES).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now